FindTrial
Sign In

denintuzumab mafodotin

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Diffuse, Large B-Cell, LymphomaFollicular Lymphoma, Grade 3bLymphoma, B-cellLymphoma, Follicular, Grade 3bLymphoma, Large B-Cell, DiffuseTransformed Lymphoma / DLBCL

Phase 2

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
TerminatedNCT02592876
Seagen Inc.Follicular Lymphoma, Grade 3b, Lymphoma, B-cell, Lymphoma, Follicular, Grade 3b +1
Start: 2015-10-31End: 2018-04-20Updated: 2019-05-17
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
TerminatedNCT02855359
Seagen Inc.Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Start: 2016-08-31End: 2018-05-15Updated: 2019-03-11

Related Papers

Denintuzumab Mafodotin Stimulates Immune Responses and Synergizes with CD20 Antibodies to Heighten Anti-Tumor Activity in Preclinical Models of Non-Hodgkin Lymphoma
Blood2016-12-023 citations
A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT).
Journal of Clinical Oncology2016-05-204 citations